Literature DB >> 18328477

Sustained morphine treatment augments basal CGRP release from cultured primary sensory neurons in a Raf-1 dependent manner.

Xu Yue1, Suneeta Tumati, Edita Navratilova, Dagmar Strop, Paul A St John, Todd W Vanderah, William R Roeske, Henry I Yamamura, Eva V Varga.   

Abstract

Recent studies suggest that sustained morphine-mediated paradoxical pain may play an important role in the development of analgesic tolerance. The intracellular signal transduction pathways involved in sustained opioid mediated augmentation of spinal pain neurotransmitter (such as calcitonin gene-related peptide (CGRP)) release are not fully clarified. Cyclic AMP (cAMP)-dependent protein kinase (PKA) plays an important role in the modulation of presynaptic neurotransmitter release. Moreover, we have shown earlier that sustained opioid agonist treatment leads to a Raf-1-dependent sensitization of adenylyl cyclase(s) (AC superactivation), augmenting forskolin-stimulated cAMP formation upon opioid withdrawal (cAMP overshoot). Therefore, in the present study we examined the role of Raf-1 in sustained morphine-mediated regulation of cAMP formation and basal CGRP release in vitro, in cultured neonatal rat dorsal root ganglion (DRG) neurons. We found that sustained morphine treatment significantly augments intracellular cAMP production as well as basal CGRP release from cultured neonatal rat DRG neurons. The selective PKA inhibitor, H-89, attenuates the sustained morphine-mediated augmentation of basal CGRP release, indicating that the cAMP/PKA pathway plays an important role in regulation of CGRP release from sensory neurons. Since our present data also demonstrated that selective Raf-1 inhibitor, GW 5074, attenuated both the cAMP overshoot and the augmentation of CGRP release mediated by sustained morphine in neonatal rat DRG neurons, we suggest that Raf-1-mediated sensitization of the intracellular cAMP formation may play an important role in sustained morphine-mediated augmentation of spinal pain neurotransmitter release.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18328477      PMCID: PMC2375088          DOI: 10.1016/j.ejphar.2008.02.013

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   5.195


  26 in total

Review 1.  Modulation of neurotransmitter release by the second messenger-activated protein kinases: implications for presynaptic plasticity.

Authors:  A G Miriam Leenders; Zu-Hang Sheng
Journal:  Pharmacol Ther       Date:  2005-01       Impact factor: 12.310

2.  Tyrosine kinase-mediated serine phosphorylation of adenylyl cyclase.

Authors:  C M Tan; D J Kelvin; D W Litchfield; S S Ferguson; R D Feldman
Journal:  Biochemistry       Date:  2001-02-13       Impact factor: 3.162

3.  Phosphorylation of adenylyl cyclase VI upon chronic delta-opioid receptor stimulation.

Authors:  E V Varga; D Stropova; M Rubenzik; S Waite; W R Roeske; H I Yamamura
Journal:  Eur J Pharmacol       Date:  1999-01-08       Impact factor: 4.432

Review 4.  Molecular and cellular basis of addiction.

Authors:  E J Nestler; G K Aghajanian
Journal:  Science       Date:  1997-10-03       Impact factor: 47.728

5.  Activation of a novel PKC isoform synergistically enhances D2L dopamine receptor-mediated sensitization of adenylate cyclase type 6.

Authors:  Michael A Beazely; Val J Watts
Journal:  Cell Signal       Date:  2005-05       Impact factor: 4.315

6.  Inhibition of neurokinin-1-substance P receptor and prostanoid activity prevents and reverses the development of morphine tolerance in vivo and the morphine-induced increase in CGRP expression in cultured dorsal root ganglion neurons.

Authors:  Kelly J Powell; Remi Quirion; Khem Jhamandas
Journal:  Eur J Neurosci       Date:  2003-09       Impact factor: 3.386

7.  Involvement of Raf-1 in chronic delta-opioid receptor agonist-mediated adenylyl cyclase superactivation.

Authors:  Eva V Varga; Marc Rubenzik; Vanessa Grife; Masano Sugiyama; Dagmar Stropova; William R Roeske; Henry I Yamamura
Journal:  Eur J Pharmacol       Date:  2002-09-06       Impact factor: 4.432

8.  Alteration of calcitonin gene related peptide and its receptor binding sites during the development of tolerance to mu and delta opioids.

Authors:  D P Ménard; D van Rossum; S Kar; R Quirion
Journal:  Can J Physiol Pharmacol       Date:  1995-07       Impact factor: 2.273

9.  A general role for adaptations in G-proteins and the cyclic AMP system in mediating the chronic actions of morphine and cocaine on neuronal function.

Authors:  R Z Terwilliger; D Beitner-Johnson; K A Sevarino; S M Crain; E J Nestler
Journal:  Brain Res       Date:  1991-05-10       Impact factor: 3.252

10.  Dexamethasone and activators of the protein kinase A and C signal transduction pathways regulate neuronal calcitonin gene-related peptide expression and release.

Authors:  S C Supowit; M D Christensen; K N Westlund; D M Hallman; D J DiPette
Journal:  Brain Res       Date:  1995-07-17       Impact factor: 3.252

View more
  15 in total

Review 1.  The mechanism of μ-opioid receptor (MOR)-TRPV1 crosstalk in TRPV1 activation involves morphine anti-nociception, tolerance and dependence.

Authors:  Yanju Bao; Yebo Gao; Liping Yang; Xiangying Kong; Jing Yu; Wei Hou; Baojin Hua
Journal:  Channels (Austin)       Date:  2015-07-15       Impact factor: 2.581

2.  Genome-Wide Small Interfering RNA Screening Reveals a Role for Cullin3-Really Interesting New Gene Ligase Signaling in Heterologous Sensitization of Adenylyl Cyclase.

Authors:  Zhong Ding; Karin F K Ejendal; Monica Soto-Velasquez; Michael P Hayes; Nicholas Santoro; Martha J Larsen; Val J Watts
Journal:  J Pharmacol Exp Ther       Date:  2019-12-19       Impact factor: 4.030

3.  Intrathecal PKA-selective siRNA treatment blocks sustained morphine-mediated pain sensitization and antinociceptive tolerance in rats.

Authors:  S Tumati; W R Roeske; T M Largent-Milnes; T W Vanderah; E V Varga
Journal:  J Neurosci Methods       Date:  2011-05-06       Impact factor: 2.390

Review 4.  Molecular Pharmacology of δ-Opioid Receptors.

Authors:  Louis Gendron; Catherine M Cahill; Mark von Zastrow; Peter W Schiller; Graciela Pineyro
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

Review 5.  Gα(i/o)-coupled receptor-mediated sensitization of adenylyl cyclase: 40 years later.

Authors:  Tarsis F Brust; Jason M Conley; Val J Watts
Journal:  Eur J Pharmacol       Date:  2015-05-14       Impact factor: 4.432

6.  Sustained morphine treatment augments prostaglandin E2-evoked calcitonin gene-related peptide release from primary sensory neurons in a PKA-dependent manner.

Authors:  Suneeta Tumati; William R Roeske; Todd W Vanderah; Eva V Varga
Journal:  Eur J Pharmacol       Date:  2010-09-15       Impact factor: 4.432

7.  Sustained morphine-mediated pain sensitization and antinociceptive tolerance are blocked by intrathecal treatment with Raf-1-selective siRNA.

Authors:  S Tumati; W R Roeske; T Largent-Milnes; R Wang; T W Vanderah; E V Varga
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

8.  Intrathecal Raf-1-selective siRNA attenuates sustained morphine-mediated thermal hyperalgesia.

Authors:  Suneeta Tumati; Tally Largent Milnes; Henry I Yamamura; Todd W Vanderah; William R Roeske; Eva V Varga
Journal:  Eur J Pharmacol       Date:  2008-10-21       Impact factor: 4.432

Review 9.  Delta Opioid Receptor Expression and Function in Primary Afferent Somatosensory Neurons.

Authors:  Amaury François; Grégory Scherrer
Journal:  Handb Exp Pharmacol       Date:  2018

10.  Sustained morphine treatment augments capsaicin-evoked calcitonin gene-related peptide release from primary sensory neurons in a protein kinase A- and Raf-1-dependent manner.

Authors:  Suneeta Tumati; Henry I Yamamura; Todd W Vanderah; William R Roeske; Eva V Varga
Journal:  J Pharmacol Exp Ther       Date:  2009-06-02       Impact factor: 4.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.